1871-76-7Relevant articles and documents
-
Pierce,Haden,Gano
, p. 408 (1945)
-
Ruthenium-catalysed one-pot regio- and diastereoselective synthesis of pyrrolo[1,2-a] indoles via cascade C-H functionalization/annulation
Singh, Sukhdev,Butani, Himanshu H.,Vachhani, Dipak D.,Shah, Anamik,Van Der Eycken, Erik V.
, p. 10812 - 10815 (2017)
A cascade approach has been developed towards dual C-C bond formation via consecutive C-H functionalization/cyclization giving access to pyrrolo[1,2-a]indoles in a highly regio- and diastereoselective manner using catalytic [Ru(p-cymene)Cl2]2. The methodology was further expanded to attain pentacyclic structures involving manifold C-C bond creation.
Triphenylacetic acid amides: Molecular propellers with induced chirality
Prusinowska, Natalia,Bendziska-Berus, Wioletta,Jelecki, Maciej,Rychlewska, Urszula,Kwit, Marcin
, p. 738 - 749 (2015)
The combination of electronic circular dichroism spectroscopy (ECD), X-ray diffraction, and theoretical calculations permitted a detailed description of an unexpected chirality transfer in triphenylacetamides, which is achieved solely through weak intramolecular interactions. The observed phenomenon proceeds as a cascade process. The triphenylacetamide chromophore is sensitive to even small changes in the relative size of the substituent attached to the stereogenic center. Substitution at the stereogenic center influences helicity of the distal trityl chromophore but does not affect its propeller shape. Deformation of the propeller shape and consequent loss of its C3 symmetry results mainly from substitution of the amide hydrogen and is connected with an increase in steric hindrance. As an outcome of our studies, a model of optical activity of chiral triphenylacetamides is proposed. The performed X-ray studies revealed that this novel class of chiral compounds is likely to be of additional value due to the porosity of the crystals.
Design and synthesis of novel N-[3-(benzimidazol-2-ylamino)phenyl]amine and N-[3-(benzoxazol-2-ylamino)phenyl]amine derivatives as potential anticancer agents
Kumar, Honnavalli Yogish,Murumkar, Prashant R.,Pawar, Vijay,Srinivasan, B. P.,Yadav, M. R.
, (2021/10/20)
In this contribution, we report the design, synthesis and cytotoxicity studies of a series of N-[3-(benzimidazol-2-yl-amino)phenyl]amine and N-[3-(benzoxazol-2-ylamino)phenyl]amine derivatives. In vitro cytotoxicity assay of 26 selected compounds was carried out at National Cancer Institute (NCI), USA. Out of them, compounds 10e (NSC D-762842/1) and 11s (NSC D-764942/1) have shown remarkable cytotoxicity with GI50 values ranging between “0.589–14.3?μM” and “0.276–12.3?μM,” respectively, in the representative nine subpanels of human tumor cell lines. Further, flow cytometry analysis demonstrated that compound 10e exerted cell cycle arrest at G2/M phase and showed dose-dependent enhancement in apoptosis in K-562 leukemia cancer cells.
Achiral Derivatives of Hydroxamate AR-42 Potently Inhibit Class i HDAC Enzymes and Cancer Cell Proliferation
Tng, Jiahui,Lim, Junxian,Wu, Kai-Chen,Lucke, Andrew J.,Xu, Weijun,Reid, Robert C.,Fairlie, David P.
, p. 5956 - 5971 (2020/06/05)
AR-42 is an orally active inhibitor of histone deacetylases (HDACs) in clinical trials for multiple myeloma, leukemia, and lymphoma. It has few hydrogen bond donors and acceptors but is a chiral 2-arylbutyrate and potentially prone to racemization. We report achiral AR-42 analogues incorporating a cycloalkyl group linked via a quaternary carbon atom, with up to 40-fold increased potency against human class I HDACs (e.g., JT86, IC50 0.7 nM, HDAC1), 25-fold increased cytotoxicity against five human cancer cell lines, and up to 70-fold less toxicity in normal human cells. JT86 was ninefold more potent than racAR-42 in promoting accumulation of acetylated histone H4 in MM96L melanoma cells. Molecular modeling and structure-activity relationships support binding to HDAC1 with tetrahydropyran acting as a hydrophobic shield from water at the enzyme surface. Such potent inhibitors of class I HDACs may show benefits in diseases (cancers, parasitic infections, inflammatory conditions) where AR-42 is active.